{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T07:01:13Z","timestamp":1769065273219,"version":"3.49.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s13256-016-1033-1","type":"journal-article","created":{"date-parts":[[2016,9,7]],"date-time":"2016-09-07T14:01:54Z","timestamp":1473256914000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Radiation recall after capecitabine in a patient with recurrent nasopharyngeal carcinoma: a case report"],"prefix":"10.1186","volume":"10","author":[{"given":"Victor","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ka-On","family":"Lam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dora","family":"Kwong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"To-Wai","family":"Leung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,9,7]]},"reference":[{"key":"1033_CR1","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2165\/00128071-200001020-00006","volume":"1","author":"W Yeo","year":"2000","unstructured":"Yeo W, Johnson PJ. Radiation-recall skin disorders associated with the use of antineoplastic drugs. Pathogenesis, prevalence, and management. Am J Clin Dermatol. 2000;1:113\u20136.","journal-title":"Am J Clin Dermatol"},{"key":"1033_CR2","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0167-8140(01)00328-0","volume":"59","author":"R Camidge","year":"2001","unstructured":"Camidge R, Price A. Characterizing the phenomenon of radiation recall dermatitis. Radiother Oncol. 2001;59:237\u201345.","journal-title":"Radiother Oncol"},{"key":"1033_CR3","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.ctrv.2005.07.008","volume":"31","author":"D Azria","year":"2005","unstructured":"Azria D, Magn\u00e9 N, Zouhair A, Castadot P, Culine S, Ychou M, et al. Radiation recall: a well recognized but neglected phenomenon. Cancer Treat Rev. 2005;31:555\u201370.","journal-title":"Cancer Treat Rev"},{"key":"1033_CR4","first-page":"209","volume":"30","author":"M Caloglu","year":"2007","unstructured":"Caloglu M, Yurut-Caloglu V, Cosar-Alas R, Saynak M, Karagol H, Uzal C. An ambiguous phenomenon of radiation and drugs: recall reactions. Onkologie. 2007;30:209\u201314.","journal-title":"Onkologie"},{"key":"1033_CR5","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1634\/theoncologist.2009-0090","volume":"15","author":"HA Burris 3rd","year":"2010","unstructured":"Burris 3rd HA, Hurtig J. Radiation recall with anti-cancer agents. Oncologist. 2010;15:1227\u201337.","journal-title":"Oncologist"},{"key":"1033_CR6","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.lungcan.2006.06.021","volume":"54","author":"F Barl\u00e9si","year":"2006","unstructured":"Barl\u00e9si F, Tummino C, Tasei AM, et al. Unsuccessful rechallenge with pemetrexed after a previous radiation recall dermatitis. Lung Cancer. 2006;54:423\u20135.","journal-title":"Lung Cancer"},{"key":"1033_CR7","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1056\/NEJMoa064320","volume":"355","author":"CE Geyer","year":"2006","unstructured":"Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Eng J Med. 2006;355:2733\u201343.","journal-title":"N Eng J Med"},{"key":"1033_CR8","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1093\/annonc\/mdr366","volume":"23","author":"C Twelves","year":"2012","unstructured":"Twelves C, Scheithauer W, McKendrick J, Seitz JF, Van Hazel G, Wong A, et al. Capecitabine versus 5-fluorouracil\/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy. Ann Oncol. 2012;23:1190\u20137.","journal-title":"Ann Oncol"},{"key":"1033_CR9","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1517\/13543784.2013.842974","volume":"22","author":"EC Popa","year":"2013","unstructured":"Popa EC, Shah MA. Capecitabine in the treatment of esophageal and gastric cancers. Expert Opin Investig Drugs. 2013;22:1645\u201357.","journal-title":"Expert Opin Investig Drugs"},{"key":"1033_CR10","doi-asserted-by":"crossref","first-page":"5513","DOI":"10.1200\/JCO.2009.24.2446","volume":"27","author":"D Cunningham","year":"2009","unstructured":"Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2009;27:5513\u20138.","journal-title":"J Clin Oncol"},{"key":"1033_CR11","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1200\/JCO.2006.09.0886","volume":"25","author":"R Herrmann","year":"2007","unstructured":"Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Sch\u00fcller J, et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol. 2007;25:2212\u20137.","journal-title":"J Clin Oncol"},{"key":"1033_CR12","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S1368-8375(02)00120-3","volume":"39","author":"DT Chua","year":"2003","unstructured":"Chua DT, Sham JS, Au GK. A phase II study of capecitabine in patients with recurrent and metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy. Oral Oncol. 2003;39:361\u20136.","journal-title":"Oral Oncol"},{"key":"1033_CR13","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1002\/hed.21884","volume":"34","author":"DT Chua","year":"2012","unstructured":"Chua DT, Yiu HH, Seetalarom K, Ng AW, Kurnianda J, Shotelersuk K, et al. Phase II trial of capecitabine plus cisplatin as first-line therapy in patients with metastatic nasopharyngeal cancer. Head Neck. 2012;34:1225\u201330.","journal-title":"Head Neck"},{"key":"1033_CR14","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00280-007-0641-2","volume":"62","author":"YH Li","year":"2008","unstructured":"Li YH, Wang FH, Jiang WQ, Xiang XJ, Deng YM, Hu GQ, et al. Phase II study of capecitabine and cisplatin combination as first-line chemotherapy in Chinese patients with metastatic nasopharyngeal carcinoma. Cancer Chemother Pharmacol. 2008;62:539\u201344.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1033_CR15","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1517\/14656566.2014.866652","volume":"15","author":"Y Gao","year":"2014","unstructured":"Gao Y, Huang HQ, Bai B, Cai QC, Wang XX, Cai QQ. Treatment outcome of docetaxel, capecitabine and cisplatin regimen for patients with refractory and relapsed nasopharyngeal carcinoma who failed previous platinum-based chemotherapy. Expert Opin Pharmacother. 2014;15:163\u201371.","journal-title":"Expert Opin Pharmacother"},{"key":"1033_CR16","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1002\/cncr.29208","volume":"121","author":"AW Lee","year":"2015","unstructured":"Lee AW, Ngan RK, Tung SY, Cheng A, Kwong DL, Lu TX, et al. Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fractionation in patients with locoregionally advanced nasopharyngeal carcinoma. Cancer. 2015;121:1328\u201338.","journal-title":"Cancer"},{"key":"1033_CR17","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1001\/archotol.1984.00800350056015","volume":"110","author":"PA Wallenborn 3rd","year":"1984","unstructured":"Wallenborn 3rd PA, Postma DS. Radiation recall supraglottitis. A hazard in head and neck chemotherapy. Arch Otolaryngol. 1984;110:614\u20137.","journal-title":"Arch Otolaryngol"},{"key":"1033_CR18","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0196-0709(91)90122-V","volume":"12","author":"BJ Wiatrak","year":"1991","unstructured":"Wiatrak BJ, Myer 3rd CM. Radiation recall supraglottitis in a child. Am J Otolaryngol. 1991;12:227\u20139.","journal-title":"Am J Otolaryngol"},{"key":"1033_CR19","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/1097-0142(19870201)59:3<411::AID-CNCR2820590310>3.0.CO;2-Z","volume":"59","author":"WA Vloten van","year":"1987","unstructured":"van Vloten WA, Hermans J, van Daal WA. Radiation-induced skin cancer and radiodermatitis of the head and neck. Cancer. 1987;59:411\u20134.","journal-title":"Cancer"},{"key":"1033_CR20","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1200\/JCO.2002.20.13.3029","volume":"20","author":"E Ortmann","year":"2002","unstructured":"Ortmann E, Hohenberg G. Treatment side effects Case 1. Radiation recall phenomenon after administration of capecitabine. J Clin Oncol. 2002;20:3029\u201330.","journal-title":"J Clin Oncol"},{"key":"1033_CR21","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.clon.2009.02.007","volume":"21","author":"N Ghosal","year":"2009","unstructured":"Ghosal N, Misra V. A case of capecitabine-induced hyperpigmentation and radiation recall phenomenon. Clin Oncol (R Coll Radiol). 2009;21:632.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"1033_CR22","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s00280-006-0223-8","volume":"58","author":"MW Saif","year":"2006","unstructured":"Saif MW, Black G, Johnson M, Russo S, Diasio R. Radiation recall phenomenon secondary to capecitabine: possible role of thymidine phosphorylase. Cancer Chemther Pharmacol. 2006;58:771\u20135.","journal-title":"Cancer Chemther Pharmacol"},{"key":"1033_CR23","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/356668a0","volume":"356","author":"T Furukawa","year":"1992","unstructured":"Furukawa T, Yoshimura A, Sumizawa T, Haraguchi M, Akiyama S, Fukui K, et al. Angiogenic factor. Nature. 1992;356:668.","journal-title":"Nature"},{"key":"1033_CR24","first-page":"495","volume":"4","author":"G Jeffrey","year":"2004","unstructured":"Jeffrey G, Truss C, Saif MW. Radiation recall syndrome associated with capecitabine. J Appl Res. 2004;4:495\u20138.","journal-title":"J Appl Res"},{"key":"1033_CR25","first-page":"2948","volume":"5","author":"N Sawada","year":"1999","unstructured":"Sawada N, Ishikawa T, Sekiguchi F, Tanaka Y, Ishitsuka H. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res. 1999;5:2948\u201353.","journal-title":"Clin Cancer Res"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-016-1033-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T22:09:15Z","timestamp":1498342155000},"score":1,"resource":{"primary":{"URL":"http:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-016-1033-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,7]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["1033"],"URL":"https:\/\/doi.org\/10.1186\/s13256-016-1033-1","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,7]]},"article-number":"247"}}